Index RUT P/E - EPS (ttm) -23.08 Insider Own 18.43% Shs Outstand 19.88M Perf Week 4.33%
Market Cap 4.89B Forward P/E - EPS next Y -17.86 Insider Trans -3.85% Shs Float 17.38M Perf Month 18.11%
Income -444.27M PEG - EPS next Q -7.49 Inst Own 96.97% Short Float 23.98% Perf Quarter -1.29%
Sales 0.00M P/S - EPS this Y -38.72% Inst Trans -1.64% Short Ratio 8.02 Perf Half Y 20.53%
Book/sh 42.80 P/B 5.36 EPS next Y 35.60% ROA -62.81% Short Interest 4.17M Perf Year -21.45%
Cash/sh 49.70 P/C 4.62 EPS next 5Y 0.00% ROE -88.78% 52W Range 119.76 - 301.00 Perf YTD -0.78%
Dividend Est. - P/FCF - EPS past 5Y -55.24% ROI -45.90% 52W High -23.73% Beta -0.42
Dividend TTM - Quick Ratio 9.39 Sales past 5Y 0.00% Gross Margin - 52W Low 91.70% ATR (14) 12.02
Dividend Ex-Date - Current Ratio 9.39 EPS Y/Y TTM -27.58% Oper. Margin 0.00% RSI (14) 53.68 Volatility 5.95% 5.14%
Employees 376 Debt/Eq 0.14 Sales Y/Y TTM - Profit Margin - Recom 1.47 Target Price 363.86
Option/Short Yes / Yes LT Debt/Eq 0.14 EPS Q/Q -74.47% Payout - Rel Volume 0.72 Prev Close 234.85
Sales Surprise - EPS Surprise -18.64% Sales Q/Q - Earnings May 07 BMO Avg Volume 519.92K Price 229.58
SMA20 5.69% SMA50 -1.07% SMA200 13.21% Trades
Volume 374,473 Change -2.24%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-22-24 Initiated BofA Securities
Underperform
$150
Mar-15-24 Upgrade B. Riley Securities
Sell → Neutral
$155 → $270
Mar-06-24 Initiated Citigroup
Buy
$382
Feb-26-24 Downgrade B. Riley Securities
Neutral → Sell
$155
Dec-20-22 Reiterated Oppenheimer
Outperform
$170 → $250
Dec-19-22 Upgrade Raymond James
Underperform → Mkt Perform
Dec-19-22 Reiterated Piper Sandler
Overweight
$203 → $280
Dec-19-22 Reiterated H.C. Wainwright
Buy
$170 → $225
Jul-08-22 Downgrade B. Riley Securities
Buy → Neutral
$131 → $75
Oct-07-21 Initiated Jefferies
Buy
$151
Aug-06-21 Upgrade BMO Capital Markets
Market Perform → Outperform
May-20-21 Resumed Goldman
Buy
$195
Nov-24-20 Resumed Evercore ISI
Outperform
$180
Nov-06-20 Reiterated H.C. Wainwright
Buy
$165 → $184
Jul-31-20 Initiated Piper Sandler
Overweight
$208
Jun-05-20 Initiated BMO Capital Markets
Market Perform
$135
May-05-20 Initiated Chardan Capital Markets
Buy
$205
Jan-30-20 Initiated Canaccord Genuity
Buy
$198
Jan-09-20 Upgrade UBS
Neutral → Buy
$125 → $127
Nov-07-19 Reiterated H.C. Wainwright
Buy
$225 → $215
Show Previous Ratings
May-24-24 03:17AM
May-21-24 09:45AM
May-17-24 03:08AM
May-15-24 09:19PM
May-10-24 08:51AM
10:53AM
Loading…
May-09-24 10:53AM
May-08-24 01:23PM
03:02AM
May-07-24 09:18AM
08:34AM
08:08AM
07:17AM
(Associated Press Finance)
07:00AM
Apr-24-24 04:00PM
Apr-23-24 08:00AM
06:00AM
Loading…
Apr-22-24 06:00AM
Apr-16-24 04:05PM
Apr-15-24 04:28PM
Apr-09-24 08:00AM
Apr-05-24 07:15AM
Apr-04-24 01:55AM
01:54AM
01:54AM
Apr-03-24 04:05PM
08:45AM
Apr-01-24 09:09PM
09:59AM
Mar-29-24 09:00AM
04:43AM
Mar-26-24 09:53AM
06:15AM
Loading…
Mar-22-24 06:15AM
Mar-19-24 05:50AM
Mar-18-24 11:58PM
08:01PM
04:47PM
04:12PM
04:04PM
03:15PM
(Investor's Business Daily)
07:00AM
(The Wall Street Journal)
Mar-17-24 08:50AM
05:50AM
Mar-15-24 04:35PM
04:14PM
(Investor's Business Daily)
03:50PM
02:34PM
(The Wall Street Journal)
01:45PM
12:56PM
12:09PM
10:17AM
10:01AM
09:30AM
07:45AM
(Investor's Business Daily)
05:35AM
Mar-14-24 04:25PM
(Investor's Business Daily) -10.77%
04:15PM
12:11PM
Mar-09-24 05:52AM
Mar-06-24 04:05PM
Mar-05-24 08:00AM
06:03AM
Feb-28-24 07:01AM
07:00AM
06:45AM
(Associated Press Finance)
Feb-26-24 04:04PM
(Investor's Business Daily)
10:52AM
(Investor's Business Daily)
Feb-23-24 05:43AM
Feb-21-24 08:00AM
Feb-13-24 01:36PM
Feb-08-24 08:00AM
Feb-06-24 04:05PM
11:29AM
(The Wall Street Journal)
11:28AM
(Investor's Business Daily)
Jan-29-24 08:00AM
02:59AM
Jan-22-24 08:00AM
01:29AM
Jan-04-24 08:00AM
01:21AM
Jan-03-24 04:30PM
Dec-30-23 06:50AM
Dec-22-23 04:30PM
Dec-19-23 01:02PM
10:16AM
Dec-15-23 11:01PM
Dec-07-23 08:45AM
Nov-27-23 04:30PM
09:50AM
Nov-24-23 10:00AM
Nov-21-23 08:00AM
Nov-17-23 10:46AM
(Investor's Business Daily)
Nov-16-23 03:03PM
Nov-15-23 04:45PM
Nov-14-23 10:56AM
Nov-13-23 04:40PM
Nov-10-23 08:00AM
07:30AM
Nov-07-23 04:54AM
Nov-06-23 08:00AM
06:29AM
(Associated Press Finance)
Nov-04-23 12:16PM
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Waltermire Robert E. Senior VP, Chief Pharma Dev. May 21 '24 Sale 231.34 1,036 239,668 5,500 May 23 09:36 PM CRAVES FRED B Director May 14 '24 Option Exercise 103.02 22,489 2,316,844 435,851 May 16 09:53 PM CRAVES FRED B Director May 14 '24 Sale 212.88 22,489 4,787,404 413,362 May 16 09:53 PM FRIEDMAN PAUL A Director Apr 08 '24 Option Exercise 9.45 26,270 248,251 212,005 Apr 10 08:50 PM Taub Rebecca Pres., R&D, and CMO Apr 08 '24 Option Exercise 9.45 2,676 25,288 461,675 Apr 10 08:53 PM FRIEDMAN PAUL A Director Apr 08 '24 Sale 246.19 26,270 6,467,491 185,735 Apr 10 08:50 PM Taub Rebecca Pres., R&D, and CMO Apr 08 '24 Sale 245.99 2,676 658,258 458,999 Apr 10 08:53 PM FRIEDMAN PAUL A Director Apr 05 '24 Option Exercise 9.45 27,613 260,943 213,348 Apr 05 08:50 PM Taub Rebecca Pres., R&D, and CMO Apr 05 '24 Option Exercise 9.45 27,506 259,932 486,505 Apr 05 08:50 PM FRIEDMAN PAUL A Director Apr 05 '24 Sale 243.40 27,613 6,721,081 185,735 Apr 05 08:50 PM Taub Rebecca Pres., R&D, and CMO Apr 05 '24 Sale 243.36 27,506 6,693,790 458,999 Apr 05 08:50 PM FRIEDMAN PAUL A Director Apr 04 '24 Option Exercise 9.45 18,710 176,810 204,445 Apr 05 08:50 PM Taub Rebecca Pres., R&D, and CMO Apr 04 '24 Option Exercise 9.45 18,537 175,175 477,536 Apr 05 08:50 PM FRIEDMAN PAUL A Director Apr 04 '24 Sale 242.96 18,710 4,545,721 185,735 Apr 05 08:50 PM Taub Rebecca Pres., R&D, and CMO Apr 04 '24 Sale 242.91 18,537 4,502,823 458,999 Apr 05 08:50 PM Taub Rebecca Pres., R&D, and CMO Apr 03 '24 Option Exercise 9.45 27,845 263,135 486,844 Apr 05 08:50 PM FRIEDMAN PAUL A Director Apr 03 '24 Option Exercise 9.45 27,407 258,996 213,142 Apr 05 08:50 PM Taub Rebecca Pres., R&D, and CMO Apr 03 '24 Sale 245.14 27,845 6,825,976 458,999 Apr 05 08:50 PM FRIEDMAN PAUL A Director Apr 03 '24 Sale 245.12 27,407 6,718,002 185,735 Apr 05 08:50 PM BATE KENNETH Director Apr 02 '24 Option Exercise 105.08 11,212 1,178,157 12,410 Apr 03 08:44 PM Daly James M Director Apr 02 '24 Option Exercise 105.08 10,912 1,146,633 12,110 Apr 03 08:41 PM BATE KENNETH Director Apr 02 '24 Sale 244.49 11,212 2,741,219 1,198 Apr 03 08:44 PM Daly James M Director Apr 02 '24 Sale 244.51 10,912 2,668,087 1,198 Apr 03 08:41 PM Daly James M Director Apr 01 '24 Option Exercise 100.79 21,577 2,174,711 22,775 Apr 03 08:41 PM BATE KENNETH Director Apr 01 '24 Option Exercise 57.96 21,277 1,233,187 22,475 Apr 03 08:44 PM Levy Richard S Director Apr 01 '24 Option Exercise 63.92 11,000 703,160 21,298 Apr 03 08:47 PM Daly James M Director Apr 01 '24 Sale 257.24 21,577 5,550,544 1,198 Apr 03 08:41 PM BATE KENNETH Director Apr 01 '24 Sale 257.26 21,277 5,473,779 1,198 Apr 03 08:44 PM Levy Richard S Director Apr 01 '24 Sale 257.48 11,000 2,832,335 10,298 Apr 03 08:47 PM Waltermire Robert E. Senior VP, Chief Pharma Dev. Dec 15 '23 Option Exercise 87.92 2,000 175,840 7,667 Dec 18 04:30 PM Waltermire Robert E. Senior VP, Chief Pharma Dev. Dec 15 '23 Sale 238.50 2,000 477,000 5,667 Dec 18 04:30 PM Waltermire Robert E. Senior VP, Chief Pharma Dev. Dec 14 '23 Option Exercise 87.92 2,000 175,840 7,667 Dec 18 04:30 PM BAKER BROS. ADVISORS LP Director Dec 14 '23 Buy 228.32 20,633 4,710,893 1,793,403 Dec 14 06:10 PM Waltermire Robert E. Senior VP, Chief Pharma Dev. Dec 14 '23 Sale 232.50 2,000 465,000 5,667 Dec 18 04:30 PM Waltermire Robert E. Senior VP, Chief Pharma Dev. Dec 13 '23 Option Exercise 87.92 2,500 219,800 8,167 Dec 14 04:30 PM BAKER BROS. ADVISORS LP Director Dec 13 '23 Buy 219.39 81,159 17,805,684 1,774,294 Dec 14 06:10 PM Waltermire Robert E. Senior VP, Chief Pharma Dev. Dec 13 '23 Sale 225.40 2,500 563,500 5,667 Dec 14 04:30 PM Waltermire Robert E. Senior VP, Chief Pharma Dev. Dec 12 '23 Option Exercise 87.92 1,300 114,296 6,967 Dec 14 04:30 PM BAKER BROS. ADVISORS LP Director Dec 12 '23 Buy 218.31 34,578 7,548,616 1,699,129 Dec 14 06:09 PM Waltermire Robert E. Senior VP, Chief Pharma Dev. Dec 12 '23 Sale 217.85 1,300 283,200 5,667 Dec 14 04:30 PM Lynch Brian Joseph SVP and General Counsel Dec 05 '23 Option Exercise 87.09 1,000 87,090 16,001 Dec 06 04:30 PM Lynch Brian Joseph SVP and General Counsel Dec 05 '23 Sale 227.33 1,000 227,330 15,001 Dec 06 04:30 PM Lynch Brian Joseph SVP and General Counsel Dec 04 '23 Option Exercise 81.16 1,800 146,090 16,801 Dec 06 04:30 PM Lynch Brian Joseph SVP and General Counsel Dec 04 '23 Sale 218.87 1,800 393,964 15,001 Dec 06 04:30 PM Lynch Brian Joseph SVP and General Counsel Nov 30 '23 Option Exercise 73.75 3,000 221,250 18,001 Dec 01 04:30 PM Lynch Brian Joseph SVP and General Counsel Nov 30 '23 Sale 204.58 3,000 613,730 15,001 Dec 01 04:30 PM Lynch Brian Joseph SVP and General Counsel Nov 29 '23 Option Exercise 73.75 4,000 295,000 19,001 Dec 01 04:30 PM Lynch Brian Joseph SVP and General Counsel Nov 29 '23 Sale 199.19 4,000 796,750 15,001 Dec 01 04:30 PM BAKER BROS. ADVISORS LP Director Nov 21 '23 Buy 188.47 64,350 12,128,340 1,667,104 Nov 21 06:15 PM BAKER BROS. ADVISORS LP Director Nov 20 '23 Buy 185.74 20,709 3,846,575 1,607,668 Nov 21 06:14 PM BAKER BROS. ADVISORS LP Director Nov 17 '23 Buy 174.70 46,370 8,100,704 1,588,541 Nov 21 06:14 PM BAKER BROS. ADVISORS LP Director Nov 15 '23 Buy 161.97 15,199 2,461,721 1,545,775 Nov 15 05:13 PM BAKER BROS. ADVISORS LP Director Nov 14 '23 Buy 154.00 37,660 5,799,653 1,500,227 Nov 15 05:12 PM BAKER BROS. ADVISORS LP Director Nov 14 '23 Buy 156.42 34,188 5,347,837 1,531,757 Nov 15 05:13 PM BAKER BROS. ADVISORS LP Director Nov 13 '23 Buy 143.21 69,839 10,001,368 1,465,494 Nov 15 05:12 PM
Index RUT P/E 18.12 EPS (ttm) 2.42 Insider Own 1.12% Shs Outstand 126.77M Perf Week -1.99%
Market Cap 5.58B Forward P/E 9.86 EPS next Y 4.44 Insider Trans -7.76% Shs Float 125.85M Perf Month 13.94%
Income 318.80M PEG 0.70 EPS next Q 0.72 Inst Own 97.96% Short Float 6.80% Perf Quarter 10.46%
Sales 862.99M P/S 6.46 EPS this Y 31.55% Inst Trans 3.78% Short Ratio 8.72 Perf Half Y 9.25%
Book/sh 1.40 P/B 31.34 EPS next Y 21.96% ROA 18.01% Short Interest 8.56M Perf Year 31.00%
Cash/sh 3.64 P/C 12.03 EPS next 5Y 26.00% ROE 261.68% 52W Range 31.86 - 46.16 Perf YTD 18.56%
Dividend Est. - P/FCF 13.17 EPS past 5Y - ROI 18.99% 52W High -5.07% Beta 1.27
Dividend TTM - Quick Ratio 5.36 Sales past 5Y 41.16% Gross Margin 69.96% 52W Low 37.54% ATR (14) 1.26
Dividend Ex-Date - Current Ratio 6.64 EPS Y/Y TTM 83.75% Oper. Margin 43.95% RSI (14) 58.03 Volatility 2.41% 3.15%
Employees 373 Debt/Eq 8.62 Sales Y/Y TTM 22.41% Profit Margin 36.94% Recom 1.36 Target Price 50.25
Option/Short Yes / Yes LT Debt/Eq 8.44 EPS Q/Q 107.45% Payout 0.00% Rel Volume 0.92 Prev Close 43.92
Sales Surprise -1.93% EPS Surprise 15.08% Sales Q/Q 20.81% Earnings May 07 AMC Avg Volume 981.16K Price 43.82
SMA20 3.25% SMA50 7.35% SMA200 12.70% Trades
Volume 898,673 Change -0.23%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-29-24 Initiated TD Cowen
Outperform
$54
Jul-24-23 Initiated H.C. Wainwright
Buy
$61
Jul-24-23 Downgrade Goldman
Buy → Neutral
$43 → $45
May-10-23 Upgrade Piper Sandler
Neutral → Overweight
$46
Mar-27-23 Resumed Berenberg
Buy
$58
Mar-16-23 Downgrade SVB Securities
Outperform → Market Perform
$42
Dec-21-22 Resumed Morgan Stanley
Overweight
$53 → $65
Nov-28-22 Initiated Wells Fargo
Overweight
$65
Sep-09-22 Initiated Morgan Stanley
Overweight
$50
May-23-22 Initiated SVB Leerink
Outperform
$52
Jun-14-21 Initiated Evercore ISI
Outperform
May-17-21 Initiated SVB Leerink
Outperform
$56
May-11-21 Downgrade Piper Sandler
Overweight → Neutral
$50 → $48
Jan-21-21 Reiterated The Benchmark Company
Buy
$46 → $59
Dec-17-20 Initiated Berenberg
Buy
$50
Sep-14-20 Resumed JP Morgan
Overweight
$28
Jul-01-20 Initiated The Benchmark Company
Buy
$39
Feb-05-20 Upgrade Piper Sandler
Neutral → Overweight
$18 → $27
Jan-09-20 Upgrade BMO Capital Markets
Market Perform → Outperform
$17 → $24
Jan-08-20 Initiated Goldman
Buy
$24
Show Previous Ratings
May-21-24 07:15AM
May-20-24 09:50AM
May-16-24 02:55PM
(Investor's Business Daily)
09:45AM
May-10-24 12:39PM
(Investor's Business Daily)
10:26AM
Loading…
May-09-24 10:26AM
06:15AM
May-08-24 03:10PM
10:34AM
08:30AM
07:05AM
(Thomson Reuters StreetEvents)
03:52AM
May-07-24 09:00PM
06:00PM
05:49PM
05:48PM
Loading…
05:48PM
05:25PM
04:23PM
(Associated Press Finance)
04:01PM
May-06-24 09:16AM
May-03-24 04:17AM
Apr-30-24 10:01AM
Apr-25-24 04:45PM
06:00AM
Apr-24-24 09:45AM
Apr-23-24 08:30AM
Apr-19-24 12:13PM
Apr-18-24 12:45PM
12:00PM
Apr-04-24 09:40AM
06:40AM
Loading…
Mar-29-24 06:40AM
Mar-21-24 11:30AM
Mar-19-24 09:40AM
Mar-14-24 01:24AM
Mar-13-24 02:25PM
Mar-12-24 02:05AM
Mar-09-24 01:07PM
Feb-29-24 03:15AM
Feb-27-24 08:30AM
Feb-21-24 11:26AM
09:00AM
06:56AM
(Thomson Reuters StreetEvents)
Feb-20-24 05:30PM
05:10PM
04:36PM
04:15PM
(Associated Press Finance)
04:01PM
Feb-14-24 09:15AM
06:49AM
Feb-13-24 10:00AM
Feb-08-24 04:30PM
Jan-29-24 04:15PM
Jan-26-24 09:45AM
Jan-25-24 05:29PM
Jan-24-24 12:10PM
Jan-22-24 09:40AM
Jan-18-24 05:01PM
08:30AM
Jan-17-24 04:01AM
Jan-16-24 08:15AM
01:15AM
Jan-12-24 09:25AM
Jan-10-24 09:45AM
Dec-15-23 03:01PM
Dec-14-23 12:45PM
Dec-08-23 09:45AM
Dec-06-23 11:30AM
Dec-05-23 09:40AM
Nov-27-23 08:00AM
Nov-20-23 12:45PM
Nov-17-23 07:03AM
Nov-16-23 09:55AM
09:00AM
Nov-09-23 10:01PM
04:43PM
Nov-08-23 05:19AM
Nov-07-23 11:22AM
(Thomson Reuters StreetEvents) +10.04%
11:21AM
11:06AM
Nov-06-23 06:00PM
05:25PM
05:10PM
04:27PM
(Associated Press Finance)
04:01PM
07:30AM
Oct-30-23 06:35PM
Oct-27-23 08:47AM
Oct-20-23 12:08PM
05:36AM
Oct-19-23 07:32AM
07:15AM
Oct-18-23 05:01AM
Oct-16-23 03:05PM
08:00AM
Oct-13-23 09:45AM
Sep-20-23 05:01AM
Sep-07-23 11:30AM
09:45AM
Sep-05-23 09:40AM
Sep-01-23 09:50AM
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER May 22 '24 Option Exercise 8.11 10,000 81,100 178,176 May 22 05:24 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER May 22 '24 Sale 45.38 10,000 453,840 168,176 May 22 05:24 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER May 21 '24 Option Exercise 8.11 10,000 81,100 178,176 May 22 05:24 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER May 21 '24 Sale 45.16 10,000 451,640 168,176 May 22 05:24 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Apr 17 '24 Option Exercise 8.11 10,000 81,100 178,176 Apr 17 07:22 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Apr 17 '24 Sale 38.49 10,000 384,890 168,176 Apr 17 07:22 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Apr 16 '24 Option Exercise 8.11 10,000 81,100 178,176 Apr 17 07:22 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Apr 16 '24 Sale 38.35 10,000 383,500 168,176 Apr 17 07:22 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Mar 26 '24 Option Exercise 11.20 11,618 130,160 168,176 Mar 26 07:38 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Mar 13 '24 Option Exercise 10.66 10,000 106,638 166,558 Mar 13 05:22 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Mar 13 '24 Sale 42.27 10,000 422,730 156,558 Mar 13 05:22 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Mar 12 '24 Option Exercise 12.07 10,000 120,700 166,558 Mar 13 05:22 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Mar 12 '24 Sale 41.64 10,000 416,370 156,558 Mar 13 05:22 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Feb 28 '24 Option Exercise 8.11 7,471 60,590 164,029 Feb 28 06:49 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Feb 28 '24 Sale 39.55 10,000 395,463 156,558 Feb 28 06:49 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Feb 27 '24 Sale 39.95 10,000 399,460 159,087 Feb 28 06:49 PM Torley Helen PRESIDENT AND CEO Feb 16 '24 Option Exercise 0.00 37,884 0 685,814 Feb 20 06:49 PM Snyder Mark Howard SVP, GENERAL COUNSEL Feb 16 '24 Option Exercise 0.00 4,796 0 14,257 Feb 20 06:55 PM LaBrosse Nicole SVP, CHIEF FINANCIAL OFFICER Feb 16 '24 Option Exercise 0.00 10,422 0 18,344 Feb 20 06:53 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Feb 16 '24 Option Exercise 0.00 10,376 0 171,247 Feb 20 06:59 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Feb 15 '24 Option Exercise 0.00 3,386 0 160,529 Feb 16 05:47 PM LaBrosse Nicole SVP, CHIEF FINANCIAL OFFICER Feb 15 '24 Option Exercise 0.00 1,254 0 11,345 Feb 16 05:41 PM Torley Helen PRESIDENT AND CEO Feb 15 '24 Option Exercise 0.00 13,092 0 651,096 Feb 16 05:39 PM Torley Helen PRESIDENT AND CEO Feb 10 '24 Option Exercise 0.00 31,281 0 654,947 Feb 13 04:12 PM LaBrosse Nicole SVP, CHIEF FINANCIAL OFFICER Feb 10 '24 Option Exercise 0.00 2,502 0 11,568 Feb 13 04:15 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Feb 10 '24 Option Exercise 0.00 8,133 0 160,044 Feb 13 04:18 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Jan 17 '24 Option Exercise 12.07 10,000 120,700 161,911 Jan 18 04:07 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Jan 17 '24 Sale 36.00 10,000 360,000 151,911 Jan 18 04:07 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Jan 16 '24 Option Exercise 12.07 10,000 120,700 161,911 Jan 18 04:07 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Jan 16 '24 Sale 36.00 10,000 360,000 151,911 Jan 18 04:07 PM Snyder Mark Howard SVP, GENERAL COUNSEL Jan 03 '24 Option Exercise 0.00 7,611 0 12,418 Jan 05 04:04 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Dec 13 '23 Option Exercise 12.07 10,000 120,700 161,911 Dec 13 07:48 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Dec 13 '23 Sale 40.39 10,000 403,940 151,911 Dec 13 07:48 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Dec 12 '23 Option Exercise 13.55 10,000 135,547 161,911 Dec 13 07:48 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Dec 12 '23 Sale 39.63 10,000 396,322 151,911 Dec 13 07:48 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Nov 15 '23 Option Exercise 13.81 10,000 138,100 161,911 Nov 16 04:18 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Nov 15 '23 Sale 39.79 10,000 397,880 151,911 Nov 16 04:18 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Nov 14 '23 Option Exercise 14.32 10,000 143,173 160,203 Nov 16 04:18 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Nov 14 '23 Sale 39.08 10,000 390,790 151,911 Nov 16 04:18 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Oct 17 '23 Option Exercise 19.98 10,000 199,800 161,911 Oct 17 07:28 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Oct 17 '23 Sale 36.52 10,000 365,200 151,911 Oct 17 07:28 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Sep 19 '23 Option Exercise 19.98 10,000 199,800 161,911 Sep 19 04:09 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Sep 19 '23 Sale 39.10 10,000 390,980 151,911 Sep 19 04:09 PM Torley Helen PRESIDENT AND CEO Aug 31 '23 Option Exercise 13.87 10,000 138,700 633,666 Aug 31 05:35 PM Torley Helen PRESIDENT AND CEO Aug 31 '23 Sale 42.82 10,000 428,170 623,666 Aug 31 05:35 PM Torley Helen PRESIDENT AND CEO Aug 30 '23 Option Exercise 13.87 10,000 138,700 633,666 Aug 31 05:35 PM Torley Helen PRESIDENT AND CEO Aug 30 '23 Sale 42.85 10,000 428,540 623,666 Aug 31 05:35 PM Torley Helen PRESIDENT AND CEO Aug 29 '23 Option Exercise 13.87 10,000 138,700 633,666 Aug 31 05:35 PM Torley Helen PRESIDENT AND CEO Aug 29 '23 Sale 42.40 10,000 424,020 623,666 Aug 31 05:35 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Aug 22 '23 Option Exercise 19.68 10,000 196,778 159,986 Aug 23 05:08 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Aug 22 '23 Sale 42.41 10,000 424,070 151,911 Aug 23 05:08 PM Torley Helen PRESIDENT AND CEO Aug 17 '23 Option Exercise 13.87 10,000 138,700 633,666 Aug 17 05:29 PM Torley Helen PRESIDENT AND CEO Aug 17 '23 Sale 43.18 10,000 431,820 623,666 Aug 17 05:29 PM Torley Helen PRESIDENT AND CEO Aug 16 '23 Option Exercise 13.87 10,000 138,700 633,666 Aug 17 05:29 PM Torley Helen PRESIDENT AND CEO Aug 16 '23 Sale 43.53 10,000 435,320 623,666 Aug 17 05:29 PM Torley Helen PRESIDENT AND CEO Aug 15 '23 Option Exercise 13.87 10,000 138,700 633,666 Aug 17 05:29 PM Torley Helen PRESIDENT AND CEO Aug 15 '23 Sale 43.77 10,000 437,680 623,666 Aug 17 05:29 PM Daly James M Director Aug 14 '23 Sale 43.74 10,000 437,410 20,503 Aug 15 04:04 PM Daly James M Director Aug 11 '23 Sale 43.71 10,000 437,110 30,503 Aug 15 04:04 PM Torley Helen PRESIDENT AND CEO Jul 27 '23 Option Exercise 13.87 10,000 138,700 633,666 Jul 27 04:03 PM Torley Helen PRESIDENT AND CEO Jul 27 '23 Sale 43.79 10,000 437,900 623,666 Jul 27 04:03 PM Torley Helen PRESIDENT AND CEO Jul 26 '23 Option Exercise 13.87 10,000 138,700 633,666 Jul 27 04:03 PM Torley Helen PRESIDENT AND CEO Jul 26 '23 Sale 42.69 10,000 426,890 623,666 Jul 27 04:03 PM Torley Helen PRESIDENT AND CEO Jul 25 '23 Option Exercise 13.87 10,000 138,700 633,666 Jul 27 04:03 PM Torley Helen PRESIDENT AND CEO Jul 25 '23 Sale 42.80 10,000 427,960 623,666 Jul 27 04:03 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Jul 18 '23 Option Exercise 15.30 20,000 306,098 151,911 Jul 19 04:10 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Jul 18 '23 Sale 40.43 10,000 404,300 141,911 Jul 19 04:10 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Jun 21 '23 Option Exercise 18.41 10,000 184,100 151,911 Jun 22 06:20 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Jun 21 '23 Sale 36.00 10,000 360,000 141,911 Jun 22 06:20 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
